Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats

Berberine (BBR) has been widely used to treat non-alcoholic fatty liver disease (NAFLD). The metabolites of BBR were believed to contribute significantly to its pharmacological effects. Oxyberberine (OBB), a gut microbiota-mediated oxidative metabolite of BBR, has been firstly identified in our recent work. Here, we aimed to comparatively investigate the anti-NAFLD properties of OBB and BBR. The anti-NAFLD effect was evaluated in high-fat...